Innate immunity genes as determinants of resistance/susceptibility to human disease : studies in leukemia patients by Almalte, Zaema
 
 
 
 
 
 
Université de Montréal 
 
 
 
Innate immunity genes as determinants of resistance/susceptibility to human disease: 
studies in leukemia patients. 
  
Par 
Zaema Salem Almalte 
 
 
 Département de Microbiologie et d’Immunologie  
Faculté de médecine 
 
 
 
Mémoire  présenté à la Faculté des études supérieures 
en vue de l’obtention du grade de Maîtrise 
en Microbiologie et Immunologie 
  
 Avril, 2010 
 
© Zaema S Almalte, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Université de Montréal 
Faculté des études supérieures 
 
 
 
  
Ce mémoire intitulé : 
 
Innate immunity genes as determinants of resistance/susceptibility to human 
disease: studies in leukemia patients. 
 
 
 
 
Présenté par : 
Zaema Salem Almalte 
 
 
 
A été évalué par un jury composé des personnes suivantes : 
 
Dr Louis de Repentigny  (président-rapporteur) 
Dr Ali Ahmad (directeur de recherche) 
Dr Carolina Alfieri (membre du jury) 
 
 
 
 
 
 
 
 
 
 
I 
 
 
 
 
Summary 
 
 
 
 
Investigating genetic determinants that play a role in conferring susceptibility/resistance 
to the development of acute B cell leukemia (B-ALL) in children is highly desirable. We 
hypothesized that activating Killer-cell Immunoglobulin-like Receptor (KIR) genes, 
which are implicated in NK cell activation, may represent one of these determinants. To 
test this hypothesis, we conducted a case-control study in French-Canadian children in 
which we used genomic DNA from 100 B-ALL patients and 245 healthy controls. The 
presence or absence of each KIR gene was detected by PCR using sequence-specific 
primers. We found that the frequencies of these genes are significantly reduced in B-ALL 
cases when compared with their healthy counterparts. Furthermore, we found that these 
genes had an additive effect in reducing risk for developing the cancer. The results may 
be useful in early identification of children at risk for developing this cancer. Moreover, 
KIR-based therapies may prove to be useful in treating this cancer. 
 
 
II 
 
 
 
 
Résumé 
 
 
La leucémie lymphoblastique aiguë des cellules Pré-B (B-ALL) reste le type de cancer le 
plus souvent diagnostiqué chez les enfants. Des études ont montré que des déterminants 
génétiques jouent un rôle important dans la susceptibilité/résistance au développement de 
ce cancer. À cet égard, les gènes Killer-cell Immunoglobulin-like Receptor (KIR) sont 
d'une importance particulière. Ces gènes sont fortement polymorphiques et codent pour 
des récepteurs qui contrôlent l’activité fonctionnelle des cellules Natural Killer (NK). 
Notre hypothèse est que les gènes activateurs des KIR s’associent avec la résistance innée 
pour développer la B-ALL. Afin d'évaluer cette hypothèse, nous avons entrepris une 
étude de cas-contrôles chez des enfants canadiens-français dans laquelle nous avons 
utilisé l'ADN génomique de 100 patients atteints de B-ALL ainsi que l’ADN de 245 
individus  sains. La présence ou l'absence de chaque gène KIR a été détectée par PCR en 
utilisant des amorces de séquences spécifiques. Nous avons trouvé que la présence des 
gènes KIR activateurs est significativement diminuée chez les enfants leucémiques  par 
rapport aux témoins. En outre, le nombre de ces gènes a aussi montré une association 
significative linéaire avec la résistance au développement d’une B-ALL. Cela suggère des 
effets additifs de ces gènes permettant de conférer une protection contre ce cancer. Ces 
résultats pourraient être utiles afin de déceler de façon précoce les enfants ayant un risque 
de développer cette leucémie. Enfin, des stratégies thérapeutiques basées sur les 
récepteurs KIR pourraient être envisagées et s'avérer utiles concernant le traitement de ce 
cancer chez les enfants. 
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CHAPTER    1 
 
 
INTRODUCTION  
 
    Approximately 15000 children are diagnosed with cancer every year in North America, 
a rate that is increasing especially among Caucasian children (1). Among the diagnosed 
childhood cancers, the most common is acute lymphoblastic leukemia (ALL) (2). Studies 
show that genetic determinants play an important role in conferring 
susceptibility/resistance to the development of this cancer in children. For example, 
mutations in several genes involved in the regulation of cell cycle, DNA repair and 
metabolism of toxic substances in the body have been associated with 
susceptibility/resistance to this cancer in children (3). It is worth noting that Natural 
Killer (NK) cells spontaneously kill tumor cells, particularly the leukemic ones (4, 5). 
Therefore, these cells are likely to play a role in controlling leukemia. The functional 
activities of NK cells are mainly regulated by Killer-cell Immunoglobulin-like Receptors 
(KIR), which are encoded by the KIR family of genes (6). Interestingly, these genes are 
highly polymorphic (7).  
    KIRs are expressed on the surface of NK and other cells and act as receptors to 
recognize specific molecular structures on the surface of target cells.  By activating or 
inhibiting NK cells, they control the functional activities of the cells. These receptors 
(especially their inhibitory versions) bind to different subsets of MHC class I antigens. 
The KIR genes encode two different kinds of receptors: activating and inhibitory, which 
activate and inhibit NK cell functions, respectively (8). The functions include killing of 
the target cells and secretion of cytokines and chemokines. The KIR gene polymorphism 
has been associated with resistance/susceptibility to infectious agents, malignancy and 
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autoimmune diseases (9, 10). However, little is known about the association of these 
genes with a child’s innate susceptibility or resistance to ALL. This issue is addressed in 
this study. In the following sections, scientific literature on leukemia, KIR genes and their 
ligands is briefly reviewed.  
1.1- Leukemia 
1.1.1- Definition 
    Leukemia is a malignant proliferation of white blood cell precursors (blasts) in bone 
marrow or lymphoid tissue and their accumulation in peripheral blood, bone marrow, and 
body tissues. The word leukemia is literally a Greek word that means “white blood”, 
referring to the color of the blood that it acquires due to accumulation of white blood 
cells.  
1.1.2- Classification 
    Leukemia in children can be classified according to time (duration of its occurrence) as 
either acute or chronic. Acute leukemia is rapidly growing and can overwhelm the body 
within a few weeks or months. On the other hand, chronic leukemia is slow growing and 
worsens progressively over years. It is worth noting that chronic leukemia is rare in 
children. Leukemia can also be classified according to the cell line that becomes 
malignant and proliferates without control. The proliferative defect can occur in the 
lymphoid or myeloid lineage, resulting in acute lymphoblastic leukemia or acute myeloid 
leukemia (AML), respectively. Eighty percent of all childhood acute leukemia is ALL 
(60 to 80% is of B origin or B-ALL, 15-20% is of T origin or T-ALL and the rest are of 
uncertain origin (11, 12).  
    ALL cells can be examined under a light microscope and can be classified 
morphologically according to the criteria established by a group of French, American and 
British (FAB) hematologists (13-15).These criteria form the basis of the so-called FAB 
classification. The FAB classification distinguishes three variants of ALL: 
ALL-L1: Most common, small uniform cells. 
ALL-L2: Less common, large varied cells. 
ALL-L3: Very rare, large varied cells with vacuoles (bubble-like features). The three 
types of ALL cells are shown in Figures 1 A, B and C.  
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          Figure 1A. L-1 stage ALL 
 
 
 
The two purple colored cells represent L-1 ALL cells. The other cells in the Figure are 
RBCs. Reproduced from Hess CE and Krstic L, 2009 (reference 14) after permission. 
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Figure 1B. L-2 stage ALL 
 
 
 
The purple colored cells represent L-2 ALL cells. These cells have more abundant 
cytoplasm than L1. Reproduced from the Website (reference 14). 
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Figure 1C. L-3 stage ALL  
 
 
 
Burkitt’s Leukemia cells are uniform in size. The cytoplasm is very basophilic (blue) and 
contains a variable number of lipid-laden vacuoles appearing as white spots. Reproduced 
from Hess CE and Krstic L, 2009 (reference 14) after permission. 
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    The WHO classification simply classifies ALL cases as precursor-B and precursor-T 
without additional categorization. The most common B-lineage ALL is the precursor-B 
phenotype with B-cell markers (CD19, CD22), TdT, cytoplasmic CD79A, CD34, CD10. 
This type has variably been called common precursor B ALL, early precursor-B ALL or 
simply B-ALL. The less common type, termed pro-B ALL, has a worse prognosis. Pre-B 
ALL is more mature than the common precursor B (16). 
    T lineage ALL accounts for only 15–20% of cases and can also be separated into 
phenotypic groups which may correspond to different stages of thymic T cell 
development (12). As in B-lineage ALL, the intermediate differentiated type is the most 
common. This common thymocyte type shows expression of the pan T-cell markers, 
CD2, cytoplasmic CD3 (cCD3), CD7, CD5 and characteristically shows coexpression of 
CD4 and CD8, and expression of CD1a. A more primitive type is called prothymocyte or 
immature thymocyte. Finally, a more mature phenotype than the common thymocyte type 
is called mature thymocyte. Again, because of a lack of conformity and variability in 
marker expression, the WHO classification recognizes only the precursor-T and -B 
groups without further immunophenotypic categorization (16). B and T lineage ALL 
phenotypes are listed in Table 1. 
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Table 1. Commonly used markers for immunophenotyping leukemia 
 
Phenotype Marker 
General CD34, HLA-DR, TdT, CD45 
B-cell markers CD10, CD19, cCD22, CD20, cCD79A, 
CD24, sIg 
T-cell markers CD1a, CD2, cCD3, CD4, CD8, CD5, CD7 
Myeloid cMPO, CD117, CD13, CD33, CD11c, 
CD14,CD15 
B-lineage ALL phenotypes: 
                           Pro-B TdT+, CD19/22/79A+, CD10–, c_–, sIg– 
                      Common precursor-B TdT+, CD19/22/79A+, CD10+,c_–, sIg– 
                           Pre-B TdT+, CD19/22/79A+, CD10+, c_+, sIg– 
                           Burkitt TdT–, CD19/22/79A+, CD10+, sIg+ 
T-lineage ALL phenotypes: 
                       Pro/immature Thymocyte TdT+, cCD3+, CD2/5/7+/– 
             Common thymocyte TdT+, cCD3+, CD2/5/7+,CD4+/CD8+, 
CD1a+ 
           Mature thymocyte TdT+/-, CD3+, CD2/5/7+, CD4+ or CD8+, 
CD1a– 
 
 
TdT: Terminal deoxynucleotidyl transferase, cMPO: Cytoplasmic myeloperoxidase; 
Modified from Larson RA and Anastasi J, 2007 (reference 16). 
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1.1.3- Signs and symptoms of ALL 
 
    As shown in Figure 2, healthy bone marrow contains stem cells, which proliferate to 
produce progeny cells that develop and differentiate into three types of cells found in 
blood: 
1. Red blood cells, which oxygenate the body in the healthy state. 
2. White blood cells, which are responsible for controlling infections and abnormal cells. 
3. Platelets, which assist in clotting to prevent blood loss. 
    In acute leukemia, cancerous cells multiply very quickly and replace normal cells. 
They takeover normal cells, as shown in Figure 3, and become permanent cells of the 
bone marrow, resulting in bone marrow failure. A person with ALL is more likely to 
bleed and have repeated infections because of fewer platelets and abnormal WBC. Other 
symptoms of acute leukemia include frequent or unexplained fever, bone and joint pain 
(as a result of the spread of lymphoblasts to the surface of the bone or into the joint from 
the marrow cavity), generalized weakness and fatigue, night- sweating, shortness of 
breath, excessive and unexplained bruising, and skin changes,  which include lumps, 
rashes, and paleness, etc. 
1.1.4- Incidence and risk factors 
 
    With the exception of leukemia, cancer in children and adolescents is rare. In North 
America, about 15000 new cases of cancer are diagnosed in Caucasian children (1).  Pre-
B ALL is the most common form of leukemia and represents about 95% of acute 
leukemia cases among children younger than 12 years of age. Most cases occur in 
children aged 3 to 7 years.  
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Figure 2. Normal hematopoietic stem cell proliferation 
 
 
 
Three types of cells are produced by hematopoietic stem cells. The cells differentiate 
progressively as shown by the arrows. Reproduced from Winslow T, 2008 (reference 17) 
after permission. 
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Figure 3. Disturbances in the relative numbers of blood cell populations 
occurring in leukemia. 
 
 
 
 
Cells are not drawn to actual scale. Reproduced from the Website (reference 18).  
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    Furthermore, it occurs slightly more often in boys than in girls, and the prognosis is 
better in girls (19). One reason for the worse prognosis in boys is the occurrence of 
testicular relapses among boys. The boys also appear to be at increased risk of bone 
marrow and CNS relapses for reasons that are not well understood (19). In contrast, acute 
myelogenous leukemia (AML) is more common in females. In addition, ALL occurs in 
Caucasian and Hispanic children more often than in black children. It may also occur in 
adults, but is not very common (20). Untreated acute leukemia is a fatal condition, 
usually because of complications that result from the infiltration of leukemic cells into 
bone marrow or vital organs. With treatment, the prognosis varies.  
    The factors that predispose children to leukemia are not fully understood. They seem to 
be complex and are likely to result from interplay between genetic make-up and 
environmental stimuli (21, 22). The risk of childhood leukemia is higher if a sibling has 
been diagnosed with the disease (3). Despite extensive studies on different molecules, 
proteomics and gene expression profiles, the exact cause of leukemia is still unknown. 
However, the clinicopathologic and molecular characterizations of different cytogenetic 
subgroups of B-ALL have been well established (23; reviewed in 24, 25). They are 
summarized in Table 2. 
    Other risk factors include exposure to very high levels of radiation, as people exposed 
to radioactive iodine radiation are much more likely to develop leukemia than those who 
have not been exposed. This is supported by the fact that the incidence of leukemia was 
increased in Japan and Chernobyl as a result of atomic bomb explosions and nuclear 
accidents, respectively (26). Internationally, the highest incidences of acute 
lymphoblastic leukemia (ALL) occur in Italy, the United States, Switzerland, and Costa 
Rica (27). 
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Table 2.Cytogenetic subgroups of pre B-ALL and their clinicopathologic features 
 
Cytogenetic 
Subgroup 
 
Frequency 
(%) 
 
Cytogenetic 
Abnormality 
Fusion Gene 
 
Unique 
Immunophenotypic 
Features 
Additional 
Molecular 
Abnormalities 
 
Pharmacologic
Features 
 
Hyperdiploid 
ALL 
 
27–29 (P) 
6–8 (A) 
 
51-65 
chromosomes 
(+4, +14,+21, 
+X) 
NA NA uncommon 
BCDG 
mutations 
(13%), FLT3 
mutations 
(21%–25%) 
Higher 
sensitivity 
to MTX, MP 
 
ALL with 
t(12;21) 
 
22–25 (P) 
1–2 (A) 
 
t(12;21) 
(p13;q22) 
 
TEL/AML1 
(ETVX/ 
RUNX1) 
 
Early pre– 
B-ALL, My+ 
 
Monoallelic 
PAX5 
deletions 
(28%) 
Higher 
sensitivity to 
asparaginase 
ALL with 
t(1;19) 
 
 
3–6 (P) 
5–7 (A) 
t(1;19) 
(q23;p13) 
 
E2A (TCF3)/ 
PBX1 
 
Pre–B-ALL, 
CD34-/dim+, 
CD20-, 
CD9++ 
NA NA 
Philadelphia1 
ALL 
 
 
2–3 (P) 
20–30 (A) 
t(9;22) 
(q34;q11.2) 
 
BCR/ABL 
(P190, 
P210) 
 
NA IKZF1 (Ikaros) 
deletions, 
BCDG 
mutations 
in 66% 
NA 
ALL with 
t(v;11q23); 
MLL 
rearranged 
 
2–3 (P) 
5–7 (A) 
 
t(4;11) 
(q21;q23) 
t(19;11) 
(p13;q23) 
 
AF4/MLL 
ENL/MLL 
 
 
Early pre-B, 
CD10-, 
CD15+, 
sCD22-, 
CD65+, 
NG2+ 
FLT3 mutations 
(18%) 
Increased 
expression of 
HOX genes 
 
Higher 
sensitivity to 
cytarabine 
Hypodiploid 
ALL 
 
 
 
5%–6% (P) 
NA (A) 
 
<46 
chromosomes 
(typically 
near 
haploid or 
low 
hypodiploid) 
NA NA BCDG 
mutations 
in 100% 
 
NA 
ALL with 
eosinophilia 
 
<1 t(5;14 
q31;q32) 
IL3/IGH NA NA NA 
 
Abbreviations: A and P in the Frequency column: % in adults and children, respectively, 
BCDG: B-cell development genes (eg, PAX5, EBF1, IKZF1, LEF1, TCF3, BLNK), 
FLT3: fms-related tyrosine kinase 3, MP: mercaptopurines, MTX: methotrexate, My: 
myeloid antigens, NA: not applicable or not known.  
Redrawn from Onciu M, 2009 (reference 24). 
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   Biological risk factors for ALL include genetic conditions such as Down’s syndrome, 
neurofibromatosis type 1, Noonan syndrome, Fanconi anaemia and Poland syndrome. 
Additionally, some environmental risk factors include prenatal exposure to nicotine or 
alcohol, prenatal exposure to X-rays and previous chemotherapy treatment (2). 
    The prognosis for ALL depends on a patient’s age, white blood cell count, the degree 
of metastasis to the central nervous system, and the initial response to chemotherapy. Bad 
prognostic risk factors include age less than one year or more than ten years at the time of 
diagnosis, high white blood cell counts, metastasis of the leukemic cells to the central 
nervous system, and absent or low response to initial chemotherapy (28). 
 
1.1.5- Treatment 
    The most common treatment used in ALL is chemotherapy. It can be administrated by 
a variety of routes including oral, intramuscular, intravenous and intrathecal (injection 
into the fluid surrounding the brain and spinal cord). Chemotherapy for ALL uses a 
combination of several anti-cancer drugs given over a long period of time (usually about 
2 years; reviewed in reference 29). The most commonly used drugs and their treatment 
protocols are listed in Table 3.Recently, monoclonal antibodies (mAB) have been used in 
the treatment of haematological malignancies, including ALL. In this regard, Rituximab, 
which is a mAb directed against the B cell lineage antigen CD20, has been used in 
combination with chemotherapy for treatment of adult lymphoma. The antibody shows 
improvement of disease-free survival in adults with non-Hodgkin’s lymphoma (NHL) 
(30). It is unlikely that mAbs will have adequate activity to be effective for paediatric 
hematologic malignancies when used alone. However, rare cases of complete remissions 
in adults and children with ALL have been reported with mAbs targeting CD20, CD33, 
and CD52 (31, 32). Radiotherapy has also been used to kill tumour cells and prevent their 
growth. 
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    The standard protocol for ALL treatment can be divided into three phases: remission-
induction, consolidation, and maintenance. Of these, the maintenance phase is the most 
prolonged.  
Remission-induction phase: The aim of this phase is to destroy leukemic cells, thereby 
placing the patient in temporary recovery, or a remission state, and restore normal 
hematopoiesis. 
Consolidation phase: In this stage, the purpose is to eradicate any remaining inactive 
leukemic cells. 
   Maintenance and re-induction phase: Long-term maintenance therapy has been found to 
decrease the risk of relapses (recurrence of leukemia). It is important to prevent relapses 
of the disease because they are more difficult to treat. Secondary remissions, if they 
occur, are usually of short duration.  
    Bone marrow or cord-blood stem cell transplantation is commonly used to treat ALL 
that has not responded to chemotherapy (reviewed in 33). This transplantation consists of 
three steps: 1) collection of healthy stem cells from a donor without cancer or from the 
patient himself or herself, 2) administration of high doses of chemotherapy and possibly 
radiation therapy to kill any remaining leukemia cells, and 3) infusion of the healthy stem 
cells to produce normal, healthy blood-forming cells. 
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Table 3 Typical ALL-treatment protocols. 
Week Treatment Schedule Chemotherapeutic class 
Continuation for high-risk patients (120 weeks) 
1 Etoposide; 
cyclophosphamide 
 Weekly Topoisomerase II inhibitor; 
alkylating agent 
2 Methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
3 Methotrexate; 
cytarabine 
Weekly Antifolate; 
cytidineantimetabolite 
4 Dexamethasone; 
vincristine 
Daily dexamethasone; 
weekly vincristine 
Glucocorticoid; 
antimicrotubule agent 
5 Etoposide; 
cyclophosphamide 
Weekly Topoisomerase II inhibitor; 
alkylating agent 
6 High-dose 
methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
7 Etoposide; cytarabine Weekly Topoisomerase II inhibitor; 
cytidineantimetabolite 
8 Dexamethasone; 
vincristine 
Daily dexamethasone; 
weekly vincristine 
Glucocorticoid; 
antimicrotubule agent 
Continuation for low-risk patients (120 weeks) 
1 Methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
2 Methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
3 Methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
4 Dexamethasone; 
vincristine 
Daily dexamethasone; 
weekly vincristine 
Glucocorticoid; 
antimicrotubule agent 
5 Methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
6 Methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
7 High-dose 
methotrexate; 
mercaptopurine 
Weekly methotrexate; 
daily mercaptopurine 
Antifolate; 
purineantimetabolite 
8 Dexamethasone; 
vincristine 
Daily dexamethasone; 
weekly vincristine 
Glucocorticoid; 
antimicrotubule agent 
Adapted from Cheok M, Evans W (reference 29). 
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1.2- Human Natural Killer (NK) Cells 
 
    NK cells are low-density large granular lymphocytes. They comprise approximately 
10-15% of all circulating lymphocytes in the bloodstream and are also present in tissues 
and lymphoid organs. NK cells have the ability to kill virus-infected or tumor cells 
without prior sensitization and for this reason are called Natural Killer cells (34). NK 
cells respond to intracellular microbes by killing the infected cell and by producing the 
macrophage activating cytokine IFN-γ. Phenotypically, NK cells are CD3-, CD2+, 
CD16+, CD56+, CD14-, and CD19-. Human NK cells can be divided into two subsets 
based on their cell-surface density of CD56 and CD16. These two markers are usually 
expressed reciprocally on two subsets of NK cells. They are divided into CD56bright 
CD16- and CD56dim CD16+ subsets. The cells in the two subsets differ in their 
proliferative potential, homing characteristics, functional capabilities and responses to 
different cytokines (listed in Table 4).  The CD3−CD56dim CD16+ subset is more 
cytotoxic, and expresses intermediate affinity receptors for IL-2 and higher levels of 
Killer-cell Ig-like Receptors (KIR). This subset comprises more than 90% of NK cells in 
blood. In contrast, the CD56brightCD16- subset has greater capacity of cytokine 
production, but has lower ability for cytotoxicity and lacks perforin granules (35, 36). 
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Table 4. Characteristics of two major human NK cell subsets. 
 
Characteristic CD56brightCD16- CD56dimCD16+ 
   
IL-2R High affinity Low affinity 
Cytotoxicity + +++ 
Cytokine productiona +++ + 
Perforin Low High 
CD62Lc High Low 
CCR7d High Low 
NKG2 Expression High Low 
IL-7R High Low 
ICAM-3 High Low 
KIR Low High 
SHIP-1e High Low 
c-Kitg High Low 
LFA-1 Low High 
CD3 -chainf Low High 
Lysozyme production Yes No 
Main location Lymph nodesb Blood 
ADCC Function Inefficient Efficient 
 
 
Abbreviations: High and Low refer to levels of expression.  
a Cytokines include IFN- , TNF- , TNF-β, IL-5, IL-13, and GM-CSF.  
b In T cell-rich areas of lymph nodes and other secondary lymphoid organs and in body 
tissues and organs such as liver.  
c,d Lymph node homing receptors.  
e Needed for IFN-  production.  
f Signaling partner for activating receptors such as CD16a.  
g c-Kit receptor tyrosine kinase needed for IL-mediated proliferation. KIR: Killer-cell Ig-
like Receptors, NKG2: NK cell group 2, CD62L: CD62 ligand. 
Adapted from Iannello A et al., 2008 (reference 7). 
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    Some immunologists also differentiate between CD16high and CD16dim subsets. They 
have described NK cells expressing both CD56 and CD16 (36a).The incubation of these 
cells with different cytokines may change their phenotypic appearance, as well as 
functional and homing characteristics. For instance, IL-2, IL-12 and IL-15 have the 
ability to convert both CD56highCD16- and CD56lowCD16+ NK cell subsets into 
CD56brightCD16+ cells (7). On the other hand, TGF-β1 converts CD16+ NK cells into 
CD16- NK cells (7, 36a). NK cells are important effectors and regulatory cells of the 
immune system.  Their important functions are given below: 
1- Defending the host against viral infections, intracellular pathogens and malignancy: 
NK cells can recognize tumor cells and virus-infected cells and kill them without prior 
sensitization to their antigens. In addition to direct killing, they secrete anti-microbial 
peptides called α-defensins. Like activated T cells, NK cells can produce interferon-γ 
(IFN-γ), so named because of its ability to inhibit or interfere with viral replication. IFN-γ 
is a potent activator of macrophages, and leads to differentiation of naive CD4+ T cells 
into T helper type 1 (TH1) effector cells (7). In addition to IFN-γ, NK cells have also 
been shown to secrete TNF-α, GM-CSF, IL-5, IL-13, IL-10, TGF-ß, MIP-1α, MIP-1ß, 
RANTES, and nitric oxide (NO). More recently, these cells were also shown to produce 
IL-22 (37). 
2- Role in pregnancy: 
NK cells function in pregnancy through their interaction with fetal extravillous 
trophoblasts to remodel maternal vasculature, and increase fetal blood supply. NK cell-
secreted IFN-γ plays a role in inducing placental vasculature (38). A failure of early 
trophoblast invasion and remodeling of the spiral arteries leads to poor blood supply to 
the placenta. This may result in pre-eclampsia, which is a disease that occurs in the third 
trimester of pregnancy (after 20 weeks). This disease is characterized by pregnancy-
induced hypertension and proteinurea. Pre-eclampsia leads to maternal and fetal mortality 
worldwide and it is the most common cause of preterm birth. Furthermore, NK cells’ 
hyperactivity is suspected of being responsible for recurrent miscarriages (three or more 
abortions) (39). Also, some studies have shown that females with recurrent miscarriages 
have significantly increased numbers of NK cells expressing activating KIR receptors 
compared to normal fertile women (40). The women carrying a high content of activating 
 
 
- 19 - 
 
KIR genes have about a threefold increased risk of developing recurrent miscarriages 
(40). 
3. Controlling leukemia:  
NK cells have a significant role in controlling the development of leukemia as they can 
kill leukemia cells growing in culture as well as in vivo in animal models (4). In addition, 
blocking of the interaction between inhibitory receptors and their MHC ligands in mice 
enhances their anti-tumor activity  and control of tumor growth (41). Moreover, leukemia 
cells can express ligands for many activating KIR receptors. This means that NK cells 
can kill tumor cells by default if they are not inhibited by the engagement of inhibitory 
KIR receptors. The role of NK cells in controlling leukemia is also suggested by the fact 
that leukemia cells do not down regulate HLA-C and HLA-Bw4, which act as ligands for 
several inhibitory receptors of NK cells. On the other hand, leukemic cells down-regulate 
HLA-A and HLA-Bw6 (42). It is of interest that NK cells do not have any receptors that 
recognize these MHC antigens. In addition to the direct killing of tumor cells, the 
activated NK cells secrete IFN-γ, which is a potent cytostatic agent (43). 
4. Role as memory cells:   
Despite being effector cells of innate immunity, NK cells have been shown to have 
immunological memory. This feature of NK cells was discovered in RAG-/-mice, which 
lack both T and B cells. The researchers discovered that recall responses to hapten-
induced hypersensitivity in these mice was mediated by NK cells (44). The exact 
mechanisms behind NK cell dependent memory or recall responses are not well defined. 
Another study using mouse models of cytomegalovirus infection showed that like T cells, 
NK cells bearing the virus-specific LY 49H receptor undergo four phases of the adaptive 
immune response (45). These phases had not been previously documented in NK cells. 
This ability of NK cells has major implications in the generation of immunological 
memory against pathogens, malignancy and vaccination strategies. 
 
 
 
 
 
- 20 - 
 
1.2.1- NK receptors (NKR) 
 
    NK cells do not have a well-defined single molecular structure to recognize target 
cells. Instead, they express a variety of molecular structures that bind to MHC and non-
MHC molecules on the target cells. NKRs can be divided into inhibitory and stimulatory 
types depending on the nature of the signal they send to NK cells after binding to their 
specific ligands. Each NK cell expresses inhibitory and stimulatory NKRs. The human 
NKR can be divided into MHC and non-MHC-binding receptors.  
 
1.2.1.1- MHC-binding receptors 
    These receptors recognize and bind MHC class I molecules. They include KIR, NKG2, 
and Ig-like transcript (ILT) families, as shown in Table 5. 
 
1.2.1.1.1-CD94/NKG2 killer lectin-like receptor (KLR)-C (NKG2/CD94 family) 
 
    These are also known as the (NK Group 2) NKG2/CD94 family of receptors. The 
genes for these receptors are located on human chromosome 12p12.3–p13.2 in a region 
called the NK gene complex (NGC). These receptors are type II, C-type, lectin-like 
integral membrane glycoproteins. This family contains four receptors: A/B (KLR-C1), C 
(KLR-C2), E/H (KLR-C3), and F (KLR-C4). B and H represent splice variants of A and 
E genes, respectively (7). 
    Of these receptors, CD94/NKG2A carries two ITIMs in its long cytoplasmic tail. It is 
expressed on a subset of human NK cells having the CD56high CD16low phenotype as well 
as on the CD56low subset of NK cells, albeit at lower levels. This receptor has an 
inhibitory function. NKG2C has a short cytoplasmic tail, links noncovalently with a 
homodimer of DAP-12, and activates NK cells upon binding with its ligands. NKG2E 
has a charged amino acid (lysine) in its transmembrane region, but it does not associate 
with DAP-12.  NKG2A and NKG2C are expressed on overlapping subsets of CD56+ NK 
cells. NKG2C and NKG2E act as activating receptors. NKG2F is a unique gene within  
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Table 5. MHC-binding receptors and their characterictics. 
 
 Gene family Ligand Expression Function 
 KIR (CD158) family HLA-C NK, T +/ - 
 (NKG2/CD94 family) HLA-E NK + 
 ILT-2 (CD85j) HLA-G NK , Mac, DC +/- 
 CD160 (BY55) HLA-C, G NK   + 
 
Abbreviations: HLA: Human Leukocyte Antigen, NK: Natural Killer cells, T: T cells, 
Mac: macrophages, DC: dendritic cells. The signs + and – indicate activating and 
inhibitory functions, respectively. 
Adapted from Iannello A et al., 2008 (reference 7).  
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the NKG2 family whose translated product contains a positively charged residue in its 
transmembrane region, an intracellular ITIM-like sequence and an extracellular domain 
(62 residues) that is truncated relative to other NKG2 molecules. The NKG2 receptors 
bind the non classical MHC class Ib molecule HLA-E (46-48). 
1.2.1.1.2-ILT (CD85) family 
    ILT or Ig-like transcripts are also known by two other names: Leukocyte Ig-Like 
Receptor (LILR) and Macrophage Ig-like Receptors (MIR) (7, 49). This family consists 
of 13 members with either inhibitory or activating properties. They are expressed on 
monocytes, macrophages, dendritic cells, and some subsets of B and T cells. A single 
member of this family ILT2 is expressed on a subset of NK cells (49). The ILT family 
members bind to classical and non classical HLA class I molecules. They are located on 
human chromosome 19 close to the KIR gene cluster. 
1.2.1.1.3-CD160 (BY55) 
    CD160 is a GPI anchored, Ig-like molecule expressed on the CD56dim subset of NK 
cells, γδ T cells, and a subset of CD8+ T lymphocytes. It binds HLA-G, HLA-C and 
other HLA molecules (50). CD160 positive NK cells and CTL usually accumulate in 
inflammatory conditions. The NK cell activation via CD160 leads to secretion of 
proinflammatory cytokines, which include IFN-γ, TNF- α and IL-6 (51). 
1.2.1.2- Non MHC-binding receptors 
    These receptors recognize molecular structures other than MHC molecules. The most 
important members of this group are discussed below, and the list of all receptors and 
their characteristics is shown in Table 6. 
1.2.1.2.1-NKG2D receptors (KLR-K1; CD314) 
 
    NKG2D are type II lectin-like receptors. They were first identified as a member of the 
NKG2 family. However, they are not typical members of this family. They are expressed 
on all human NK cells, and their expression is upregulated by IL-15 and IL-12. On the 
 
 
- 23 - 
 
reverse, certain other cytokines e.g., TGF-β and IL-10 decrease their expression. They are 
also expressed on resting and activated human CD8+ T lymphocytes (7, 52). 
    NKG2D receptors do not recognize and bind HLA-E, as do all members of the 
CD94/NKG2 family. Instead, they bind MICA, MICB and HCMV-induced ULBPs (53; 
reviewed in 54; shown in Figure 4). The MIC genes are highly polymorphic, and are 
located on human chromosome 6q25 outside the MHC locus. The ligands for NKG2D are 
usually not expressed under physiological conditions. However, they are induced on body 
cells in response to stress, DNA damage, infection and malignancy. The expression of 
these ligands on body cells flags them for destruction by NK cells via NKG2D (54, 55).  
In addition to having different ligands, NKG2D also differs from other members of the 
NKG2 family; it does not need CD94 for expression on the cell surface (55). 
1.2.1.2.2- Natural cytotoxicity receptors (NCRs) 
    There are three NCRs: NKp46 (CD335), NKp30 (CD337), and NKp44.  NKp46 and 
NKp30 are expressed on resting and activated NK cells, whereas NKp44 is expressed 
only on cytokine-activated NK cells. The engagement of these receptors with their 
ligands triggers NK cell-mediated killing and secretion of IFN-γ. The ligands for the 
NCR mostly remain unknown (7). Only NK46 and NKp30 were reported to recognize the 
haemagglutinin antigen (HA) of the influenza virus (56). 
1.2.1.2.3- SLAM-related Receptors (SRRs) 
    The signalling lymphocytic activation molecule (SLAM) family of receptors is 
expressed by a wide range of immune cells. Through their cytoplasmic domain, the 
SLAM family receptors associate with SLAM-associated protein (SAP) and SAP-related 
molecules.  SLAM (CD150) is expressed on the surface of T cells (57,58).  
   The SRR family includes 2B4 (CD244), NTB-A (Ly108), and CD2-like Receptor on 
Activated Cytoxic Cells (CRACC; CD139). These receptors are related to SLAM, as they 
all use similar signalling molecules, SAP or related molecules. The genes for SSRs are 
located on human chromosome 1q22. They are expressed on NK cells, monocytes, 
basophils, γδ T cells and CD8+ T cells of the effector memory phenotype (7, 57).  
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1.2.2- NK cell Co-receptors 
 
    Co-receptors usually add to the strength of activating signal. These molecules 
themselves are unable to trigger NK cell functions. According to this definition, some co-
receptors may be able to trigger NK cell functions under certain conditions and therefore 
may qualify as receptors. For example, the Lymphocyte Function-associated Antigen 1 
(LFA-1) can trigger NK cell-mediated lysis under appropriate conditions, and could be 
considered as an activating receptor (59).  
    NK cells express several coreceptors, which bind to their cognate ligands on target 
cells and send co-stimulatory signals. These signals add to the overall strength of the 
activating signal. Adhesion molecules, such as integrins, selectins, and several Ig-like 
molecules usually act as co-receptors for NK cells. Table 7 lists NK cell co-receptors, 
their expression and function. 
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Table 6. Non MHC-binding NK cell receptors. 
Receptor Expression Ligands Function 
NKG2D NK,CD8+T MICA, MICB, 
ULBPs 
+ 
NKp46 NK HA + 
NKp44 Activated NK HA + 
NKp30 NK ? + 
NKR-P1 (CD161; 
KLR-B1) 
NK, NKT, CTL LLT-1 +/– 
2B4(CD244) NK , T, Monocytes, 
Basophils 
CD48 +/– 
KLR-G1 Mast cells, NK , 
CTL 
Cadherens – 
FcRL B cells, NK IgG complexes – 
NKp80 NK AICL + 
DNAM-1 NK, B cells Nectin-2, PVR + 
Four Ig-like B7 
homologues 
(4IgB7H or B7H) 
NK,T PD-1 +/– 
SIGLEC-7 NK Sialic acid – 
CEACAM-1 
(CD66a) 
NK CEA and CEA- 
related Proteins 
– 
LAIR Leukocytes Collagen –? 
CEA: Carcinoembryonic antigen; CEACAM-1: CEA-related cell adhesion molecule; 
FcRL6: FcR-like protein 6; SAP: Signaling Lymphocyte Activating Molecule (SLAM)-
Associated Protein; SIP: Stress-induced proteins [MICA, MICB, UL16-binding protein 
(ULBP)]; DNAM-1: DNAX accessory molecule 1; SIGLEC-7: Sialic acid-binding Ig-
like lectin 7. The designations (+),   (–), and (+/–) indicate that the function is activation, 
inhibition, and both, respectively. Redrawn from Iannello A et al., 2008 (reference 7). 
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Figure 4. Non-MHC-binding NK Cell Receptors. 
 
 
 
 
ITSM: Immunoreceptor tyrosine-based switch motif; Col: Collagens; NTB-A: NK-T-B: 
NK, T-B cell antigen; LAIR-1:  Leukocyte-associated Ig-like Receptors. The YxxM 
motif, when phosphorylated, recruits PI-3K. Not drawn to scale. The question mark (?) 
indicates that the ligand is unknown. Reproduced from Iannello A et al., 2008 (reference 
7) after permission.  
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Table7. Human NK cell co-receptors, their expression and function. 
 
N-CAM: Neural cell adhesion molecule; VCAM: Vascular cell adhesion molecule; 
MAdCAM: Mucosa addressin cell adhesion molecule.  
Adapted from Iannello A et al., 2008 (reference 7). 
Name Ligand Expression Function 
CD2 (LFA-2) D58 (LFA-3) 
CD48 (weakly) 
All NK Costimulation, adhesion 
LFA-1 
(CD11a/CD18) 
CD54 (ICAM-1–5) All NK Costimulation, adhesion 
Cytoskeleton 
rearrangement 
CD8 MHC class I Subset Costimulation, adhesion 
CD69 Unknown Activated 
NK 
Costimulation 
CD56 (N-
CAM) 
Self Subset Homotypic adhesion 
CD59 C8, C9 All NK Adhesion, costimulation 
CD57 Unknown Subset Marker of senescence 
CD28 B-7 Fetal NK Costimulation 
CD27 CD70 Subset Costimulation 
CD44 Hyaluronic acid Activated 
NK 
Costimulation, adhesion 
VLA-4 Fibronectin, 
VCAM-1 
MAdCAM-1 
Subset Adhesion, diapedesis 
VLA-5 Fibronectin Subset Adhesion, diapedesis 
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1.3- KIR family of NKRs 
 
    The KIRs (Killer-cell Immunoglobulin-like Receptors) are so named because they 
share structural homology to immunoglobulin molecules. They are type I integral 
membrane glycoproteins. They are usually expressed as monomers on the surface of 
natural killer (NK) cells. These receptors play an important role in controlling NK cell 
activities. To date, fifteen KIR genes, which include two pseudo genes, have been well 
described. These genes are located on human chromosome 19q13.4 in a tandem head to 
tail fashion in a short 150 kb region called the Leukocyte Receptor Complex (LRC). The 
structure of a typical KIR gene and the receptor is shown in Figure 5.  
    Each KIR has an extracellular region, a stem, a transmembrane region and a 
cytoplasmic tail. The extracellular region binds the receptor ligand and consists of two or 
three immunoglobulin (Ig)-like domains. The cytoplasmic tail may be short or long. Each 
long-tail KIR has two immunoreceptor tyrosine-based inhibitory motifs (ITIM) and is 
inhibitory in function. When the receptor binds to its ligands, the tyrosine residues in the 
tail become phosphorylated and recruit SH-2 domain-containing phosphatases: SHP-1 
and 2. These phosphatases dephosphorylate several substrates involved in the NK cell 
activation cascade.  Dephosphorylation transiently inhibits NK cells from triggering their 
effector functions (60). 
    The KIR receptors with a short cytoplasmic tail possess a charged amino acid (lysine) 
in their transmembrane regions and associate non-covalently with an adaptor protein 
called KARAP/DAP-12, which has immunotyrosine-based activating motifs (ITAMs) in 
its cytoplasmic tail. Upon binding to the MHC-ligands, the tyrosine residues in the 
ITAMs become phosphorylated, recruit several kinases and ultimately trigger NK cell-
mediated killing and cytokine secretion.  Each KIR gene has been named according to  
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Figure 5. The structure of a typical KIR gene and the receptor. 
 
 
A typical KIR gene comprises nine exons shown here on the right side of the figure. 
Double horizontal lines in the gene indicate introns. The schematic structure of the 
encoded receptor is shown on the left. The part of the receptor encoded by each 
individual exon is also indicated. The scissor in the figure indicates cleavage site for the 
signal peptide. The letters N and C designate N- and C-terminals of the protein, 
respectively. D0, -1, -2: Extracellular Ig-like domains; TM: Transmembrane region. Not 
drawn to scale. Reproduced from Iannello A et al., 2008 (reference 7) after Publisher’s 
permission. 
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the number of immunoglobulin-like domains in the extracellular regions and the length of 
the cytoplasmic tail present in its encoded receptor. In this taxonomy, 2D refers to two 
domain-, and 3D refers to three domain-receptor encoding gene. The letters (L) refer to 
long tail and (S) to short tail encoding genes. For example, KIR2DL1 means a gene that 
encodes a receptor having two extracellular domains and a long tail. The final number 
differentiates between individual KIR genes in each group. 
    The inhibitory KIR genes discovered so far include KIR2DL1, KIR2DL2/3(alleles), 
KIR2DL4, KIR2DL5a, KIR2DL5b, KIR3DL1, and KIR3DL2 (61, 62). The six activating 
genes include KIR2DS1-5 and KIR3DS1. All activating KIR genes represent 
independent loci on the chromosome. However, KIR3DS1 represents allelic variants of 
KIR3DL1 and encodes short tailed activating receptors (61, 63). KIR2DL4 is an unusual 
KIR; it is not expressed clonally on NK cells as other inhibitory KIRs are (64). It is 
expressed on all NK cells in all humans, and it expresses an inhibitory ITIM in its 
cytoplasmic tail but also expresses a charged amino acid (arginine) in its transmembrane 
region and interacts covalently with its signaling partner, the γ chain of FcεRI(64). In 
other words, it exhibits dual characteristics of an activating and an inhibitory KIR. The 
receptor interacts with HLA-G (a non classical MHC class Ib antigen). 
1.3.1- The KIR ligands 
 
    The two-domain KIRs bind HLA-C antigens. These antigens are divided into group I 
and II, which are characterized by the presence of an asparagine and a lysine at position 
80 in their amino acid sequences, respectively. KIR2DL1 and its allelic forms encode 
receptors that recognize group II HLA-C antigens (HLA-Cw1, 3, 7, 8, 13 and 14). On the 
other hand, KIR2DL2 and KIE2DL3 recognize group I HLA-C antigen (HLA-Cw2, 4, 5, 
6, 17 and 18). It is noteworthy that all the known HLA-C molecules in humans (Cw1-18) 
are recognized by either KIR2DL1 or 2DL2/3 receptors (65-69). The affinity of different 
KIRs to bind their respective HLA-C ligands differ from one to another, e.g., KIR2DL1 
binds with high affinity to their group II HLA-C ligands, whereas KIR2DL3 binds with 
its group I HLA-C ligands relatively weakly. The allelic variant KIR2DL2 binds with its 
HLA-C ligands with intermediate affinity. These binding characteristics have an 
important impact on NK cell functions. For example, in a person who is homozygous for 
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group II HLA-C and co-expresses KIR2DL1, NK cells will be under tight inhibition 
compared to a person who is homozygous for group I HLA-C and co-expresses 
KIR2DL3 (62-66). The three-domain KIR3DL1 and its activating allotype KIR3DS1 
bind the HLA-Bw4 serospecificity molecules, which have isoleucine at position 80 (70, 
71). Their binding to the HLA-Bw4 serospecific molecules that have threonine at 
position 80 is relatively weak. It is worth mentioning that HLA- B allotypes have two 
mutually exclusive serotypes, namely Bw4 or Bw6. HLA-Bw4 antigens could have 
threonine or isoleucine at postion 80 of their amino acid sequence. It is noteworthy that 
different KIR3DL1 allotypes also vary in their affinity for their HLA-Bw4 ligands. The 
activating short-tailed KIRs have been shown to bind HLA-ligands with very low 
affinities compared to the inhibitory KIR receptors (67). Table 8 lists KIRs, their 
distribution, signaling partners and ligands. 
1.3.2- KIR haplotypes 
 
KIR genes vary from one person to another. The degree of diversity in the KIR genes 
matches that found in HLA genes. There are two mechanisms that contribute to this 
diversity: 
(1) KIR haplotypes differ in gene content.  
(2) KIR genes are highly polymorphic.  
Because of this diversity, unrelated individuals rarely have identical KIR genotypes.  
Based upon their gene contents, KIR haplotypes can be divided into two distinctive 
groups: A and B.  
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Table 8. Human KIRs (CD158) and their ligands. 
 
Receptor Distribution Signaling 
partner 
Ligand 
( I ) Activating KIR    
 1. KIR2DS1 (p50.1) NK DAP-12 HLA-C II, ? 
 2. KIR2DS2 (p50.2) NK DAP-12 HLA-C I, ? 
 3. KIR2DS4 (p50.3) NK DAP-12 HLA-Cw4, ? 
 4. KIR2DS3, 5 NK DAP-12 ? 
 5. KIR3DS1 (p70) NK DAP-12 HLA-Bw4-I, ?
    
( II ) Inhibitory KIR    
 1. KIR2DL1 (p58.1) NK, CTL SHP-1, 2 HLA-C II 
 2. KIR2DL2/3 (p58.2) NK, CTL SHP-1, 2 HLA-C I 
 3. KIR3DL1 (p70;   
NKB1) 
NK, CTL SHP-1, 2 HLA-B Bw4 
 4. KIR3DL2 (p140) NK, CTL SHP-1, 2 HLA-A3, A11
 5. KIR2DL4 NK Fc R1 -chain HLA-G 
 6. KIR2DL5 NK, CTL SHP-2 HLA-G? 
 
Activating KIRs may be expressed on CD4+ T cells in some disease conditions but are 
rarely expressed on CTL. HLA-Bw4-I designates Bw4 allotypes having isoleucine at 
position 80. The question mark (?) indicates unknown and/or controversial ligands. All 
KIRs are expressed clonally on overlapping subsets of NK cells except KIR2DL4, which 
is expressed on all NK cells. Inhibitory KIRs are also expressed on the CTL of the 
effector/memory phenotype. Adapted from Iannello A. et al., 2008 (reference 7). 
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Group A haplotypes are less variable. They lack stimulatory KIR genes except for 
KIR2DS4. Interestingly, KIR2DS4 frequently carries a 22 bp deletion in its exon 5 and 
encodes a non-functional receptor (72). In general, the group A haplotypes are composed 
of a fixed content of seven KIR genes and two pseudogenes, and are diversified through 
allelic polymorphism (reviewed in 73). 
Group B haplotypes have a variable number of KIR genes that are not present in group A 
haplotypes (e.g., KIR2DS1, 2DS2, 2DS3, 2DS5, 3DS1, and 2DL5). They often, but not 
always, lack KIR 2DS4. B haplotypes exhibit more diversity both in terms of gene 
content and allelic polymorphism. There are four genes that are found in both groups of 
haplotypes and are called framework genes. They include KIR3DL2 on the telomeric 
end, 3DL3 on the centromeric end, and KIR2DL4 and KIR3DP1 in the central region 
(Figure 6; 62, 65, 72, 73). 
 
1.3.3- KIR-HLA epistatic interactions and disease outcome 
 
    The genes of the KIR family are highly polymorphic. KIRs bind epitopes, which are 
displayed on a subset of related MHC class I antigens. The KIR genes encode either 
activating or inhibitory receptors. The inhibitory receptors bind with their specific ligands 
on the target cell and inhibit the NK cell from killing the target cell as well as from 
secreting chemokines and cytokines. Each inhibitory KIR has a different affinity for its 
MHC ligand, which means that the level of inhibition exerted by a given KIR/ligand pair 
is different from the other pairs. It is of interest to note that the genes for the KIR ligands 
(e.g., MHC class I antigens) are also highly polymorphic. Furthermore, the genes for KIR 
and MHC class I antigens in humans are found on chromosomes 19 and 6, respectively,  
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Figure 6. KIR Haplotypes. 
 
 
 
The framework genes (3DL3, 3DP1, 2DL4, and 3DL2; in violet color) are present in each 
haplotype. The figure shows KIR genes present in centromeric and telomeric halves of 
the frequently found A and B haplotypes above and below the framework genes, 
respectively. Each box in the figure represents a KIR gene. 3DP1 is a pseudogene. 
Reproduced from Iannello A et al., 2008 (reference 7) after permission. 
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meaning that during meiosis they segregate independently from one another. This would 
create different combinations of KIR and MHC ligand genes for each individual, which 
would then affect the activity of their NK cells and their ability to control tumor growth. 
For example, an individual with a combination of KIR and MHC ligands that tightly 
inhibit NK cells may be more at risk for developing leukemia (66, 73). 
    There is also another NK activating receptor, NKG2D, which has very low genetic 
variability, but whose ligands (MHC class I heavy chain-related protein A: MICA, and 
MICB) are very polymorphic (55). Similarly to KIR and its ligands, NKG2D has 
different binding affinities for various forms of MICA and MICB. Therefore, different 
NKG2D ligands vary in their ability to activate NK and T cells in different individuals. 
Because of this, an individual’s NKG2D ligands may control the level of activation of 
his/her NK cells, which can then affect his/her risk of developing leukemia. 
   
1.3.4- Effects of KIR genotypes on human disease 
    Genetic studies on the association of KIR with diseases have been mainly carried out 
in viral infections and autoimmune diseases. Figure 7 shows a model for the association 
of KIR with different diseases. According to this model, the individuals carrying KIR and 
HLA gene combinations (e.g., those homozygous for KIR2DL1 and HLA-CLYS80 genes, 
with no activating KIR gene) that inhibit NK cells relatively tightly would be less likely 
to develop autoimmune diseases. Such individuals may suffer from pre-eclampsia and are 
likely to be more susceptible to viral infections and malignancy. On the other hand, the 
individuals with the KIR-HLA gene combinations (e.g., KIR2DL3 and HLA-CASP80 with 
one or more activating KIR genes) that inhibit NK cells to the minimum are likely to 
control viral infections and malignancy. However, this model predicts that such 
individuals would suffer more from autoimmune diseases and may experience repeated 
spontaneous miscarriages (73). In fact many studies concerning the associations of KIR 
and HLA genes with innate resistance/susceptibility to autoimmune diseases, 
malignancy, control of viral infections and reproductive success in humans have verified 
the predictions made by this model (10, 73- 78). Activating KIR genes, which encode 
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NK cell activating receptors, have also been reported to affect outcomes of many human 
diseases. In line with the model, several activating KIR genes have shown significant 
associations with autoimmune diseases. The first of these was KIR2DS2, which was 
associated with the development of vasculitis in rheumatoid arthritis (10). Another 
group found that patients with acute coronary syndrome share common features with 
those diagnosed with rheumatoid vasculitis (10, 79), indicating association of KIR 
genotypes and vascular disease. 
 
1.3.5-KIR genes in leukemia 
 
    A few earlier studies described an association of KIR genes with leukemia (9,74, 
80,81; reviewed in 82). Unfortunately all these studies were performed on adult leukemic 
patients. One group studied the relationship between certain inhibitory KIR-HLA 
interactions and chronic lymphoid and myeloid leukemia in the Belgian adult leukemic 
patients (9).  Their study subjects mostly had other types of leukemia; only 8 cases were 
ALL. They found significant associations of certain inhibitory KIR haplotypes with some 
forms of leukemia; however the number of patients with ALL was too low to find any 
significant association. These workers conducted another study in Polish and German 
adults suffering from Myeloid or Chronic Lymphocytic Leukemia and found significant 
associations with certain combinations of inhibitory KIR and their HLA ligands (74). The 
study had no participants with ALL. Another study (80) reported significant association 
of the intact KIR2DS4 gene with innate resistance to CML in humans but not with 
resistance to ALL. The number of the leukemic patients with ALL was very low (only 
21) in this study. Due to this low number of participants with ALL, the study had not 
enough power to detect associations between KIR2DS4 and ALL. In a relatively recent 
study in a Chinese population (81), researchers found that activating KIR genes were 
more common in CML patients than in healthy controls, although only the difference for 
the KIR2DS4 gene reached statistical significance. This study did not differentiate 
between the functional and mutant variants of the KIR2DS4 gene. The researchers also 
found a significantly decreased frequency of KIR2DS3 in ALL patients compared to the  
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Figure 7. Genetic model for association of KIR with human diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This model is based on KIR genotypes and KIR:HLA combinations that are considered to 
provide different levels of inhibition and activation, and on disease studies in which an 
association with protection or susceptibility was associated with specific KIR genes, or 
specific KIR and HLA combinations.  
Adapted from Williams AP et al., 2005 (reference 73). 
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control group (81). We were unable to find any study in the literature that studied the 
potential association of activating or inhibitory KIR genes in childhood leukemia.  
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CHAPTER 2 
 
 
AIMS AND OBJECTIVES 
 
    The aim of this study was to investigate the associations between activating KIR genes 
and acute lymphocytic leukemia (B ALL), which is the most common form of leukemia 
affecting children under 15 years of age. As stated earlier, humans differ from each other 
with respect to the number of inherited activating KIR genes. They may have 0-6 of these 
genes. Since the receptors encoded by the genes enhance NK cell activation and overall 
immune competence of the individual, we hypothesized that their inheritance is likely to 
protect individuals from developing this cancer. 
    The specific objectives of the study were to compare the frequencies of activating KIR 
genes between B-ALL patients and healthy controls in French-Canadian children, and 
determine whether these genes showed significant association with resistance or 
susceptibility to this cancer in this population.   
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CHAPTER 3      
 
 
RESULTS 
 
    The results obtained from the investigations conducted on the genomic DNA obtained 
from B-ALL patients and control subjects were compiled into a research article. The 
article is reproduced in this chapter. 
 
 
- 41 - 
 
Association of activating Killer-cell Immunoglobulin-like Receptor genes with 
decreased risk for developing B cell acute lymphoblastic leukemia in children 
 
Zaema Almalte1, Suzanne Samarani1, Alexandre Iannello1, Olfa Debbeche1, 
Devendra K Amre2, Daniel Sinnett2 and Ali Ahmad1 
 
Laboratory of Innate Immunity1, CHU Sainte-Justine Research Center1,2, Department of 
Microbiology & Immunology1, Department of Pediatrics2, University of Montreal1,2, 
Montreal, Quebec, Canada 
 
 
 
 
Running Title: Association between activating KIR genes and risk for B-ALL 
 
 
Correspondence: 
Ali Ahmad 
 
Laboratory of Innate Immunity, CHU Sainte-Justine Research Center/Department of 
Microbiology & Immunology, 3175 Cote Ste-Catherine, Montreal, Qc, H3T 1C5, Canada 
 
Tel: 514-345-4931 ext 6157 
 
Fax: 514-345-4801 
 
 
 
 
- 42 - 
 
 
 
ABSTRACT 
 
Pre-B cell acute lymphoblastic leukemia (B-ALL) is the most frequent form of leukemia 
affecting children under 15 years of age. Evidence is accumulating that genetic factors 
play an important role in conferring susceptibility/resistance to leukemia. In this regard, 
the Killer-cell Immunoglobulin-like Receptor (KIR) genes are of particular interest. 
These genes are highly polymorphic and encode receptors that control functional 
activities of Natural Killer (NK) cells, which are known to kill leukemia cells and 
regulate immune responses both in vitro and in vivo. However, little is known concerning 
the role of these genes and/or their variants in conferring innate susceptibility/resistance 
to the childhood leukemia. In this study, using a case-control design, we have addressed 
this issue. Our results show that harbouring activating KIR genes confers protection from 
this cancer in French-Canadian children. The protection increases as the number of these 
genes increases in an individual. These results provide novel insights concerning 
pathogenesis as well as for potential immunotherapy in children affected with Pre-B 
ALL.  
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INTRODUCTION 
 
Each year about 15,000 new cases of leukemia are diagnosed in North America. Acute 
lymphoblastic leukemia (ALL) represents about 95% of these cases occurring in children 
under fifteen years of age. About 85% of the ALL cases in children involve Pre-B cells 
(1). The pre-B ALL is also the most deadly form of leukemia occurring in children. 
Cumulative evidence suggests that the genetic make up of an individual plays an 
important role in determining innate resistance/susceptibility of an individual to the 
development of this leukemia. In this respect, several genetic determinants that influence 
cell proliferation and cell cycle progression have been shown to be associated with 
susceptibility/resistance to develop Pre-B ALL in children (2-5; reviewed in 6). However, 
little is known about the role of the Killer-cell Immunoglobulin-like Receptor (KIR) 
genes in the development of this leukemia. 
The KIR gene family comprises sixteen genes located in a head-to-tail fashion on human 
chromosome 19q13.4 in a 150 kb region called “Leukocyte Receptor Complex or LRC” 
(7, 8). The genes in the family are highly polymorphic and are rapidly evolving. Of the 
sixteen KIR genes, seven inhibitory genes (KIR3DL1-3, KIR2DL1, KIR2DL2/3 and 
KIR2DL5A and B) encode receptors with long-tailed cytoplasmic tails and inhibit the 
functions of the immune cells. Each inhibitory receptor binds to public epitopes present 
in a group of related MHC class I antigens (9, 10). The KIR family also contains six 
activating genes (KIR3DS1, KIR2DS1-5) that encode receptors with short cytoplasmic 
tails. The binding of the activating receptors to their cognate ligands on a target cell 
results in activation of the immune cells. In the case of Natural Killer (NK cells), this 
activation leads to killing of the target cell as well as secretion of soluble mediators like 
IFN-γ and TNF-α. It is noteworthy that KIR haplotypes may vary from one another with 
respect to the number of activating KIR genes and have been divided into two groups: A 
and B. The group A haplotypes carry only one activating KIR gene, KIR2DS4, which is 
often mutated and encodes a non functional receptor. The group B haplotypes usually 
lack KIR2DS4 but contain 1-5 other activating KIR genes. Consequently, individuals 
differ from each other with respect to the number of inherited activating KIR genes (7, 8). 
Several studies have shown that KIR genotypes as well as the number of activating KIR 
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genes inherited by an individual influence his/her resistance/susceptibility to infectious 
agents, development of autoimmune diseases, reproductive efficiency, graft versus host 
disease (GVHD) and cancer (11-16; reviewed in 17). Certain activating KIR genes have 
been shown to protect humans from non-Pre B ALL (18). However, little is known 
concerning the impact of activating KIR genes on the innate resistance/susceptibility to 
develop the childhood leukemia pre-B ALL. We addressed this issue in this study and 
show here that all activating KIR genes protect children from developing pre-B ALL. 
Furthermore, we also observed that the individuals who harbour higher numbers of 
activating KIR activating were afforded more protection from this childhood leukemia.  
 
MATERIALS and METHODS 
Patient Population: 
In order to investigate associations between activating KIR genes and pre-B ALL, we 
carried out a case-control study at the CHU Sainte-Justine Research Center, Montreal. 
Cases of pre-B ALL patients (N=102) were recruited from the Hemato-Oncology clinic 
of the hospital during 1989-2004 and included children diagnosed prior to age 18.  They 
had the following characteristics: (a) girls to boys’ ratio of 40:60; (b) age at diagnosis: 
9% between 0-1 year, 70% between 2-10 years, and 21% between 10-18 years. Diagnosis 
of pre-B ALL was based on established criteria that included: histological examination of 
the blood and bone marrow smears, immunophenotyping of the lymphoblasts. 
Given the potential heterogeneity in the distribution of KIR gene frequencies even within 
seemingly ethnically homogeneous populations, controls (N=250) were selected from 
different sources to enhance population representation. These included children visiting 
the orthopaedic department of the study hospital for minor fractures, their siblings, a 
sample of population-based children. Only controls without pre-B ALL, other cancers or 
autoimmune disorders were included. These controls have been previously utilized for 
replicating or confirming associations between a number of susceptibility genes and 
complex diseases such as inflammatory bowel diseases (IBD) (19-21). Both cases and 
controls were restricted to those who described themselves as French-Canadian, and were 
residing in Quebec at the time of recruitment. The relevant demographic, clinical and 
histopathological data were extracted from the medical records of these patients or from 
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their parents. Blood and/or saliva samples were collected from the participants as a 
source of DNA. 
Genomic DNA from blood and saliva was extracted by salting out technique and/or 
commercial kits (Oragene). The quantity and quality of the extracted DNA samples were 
determined by UV spectrophotometry. The samples were coded and kept at the Banks 
maintained at the CHU Sainte-Justine Research Center. 
The study was approved by the Institutional Ethics committee, and written informed 
consent was obtained from all the participants. 
 
KIR Genotyping: 
 
The genomic DNA samples from the patients and control subjects were analysed for the 
presence or absence of individual activating KIR genes using PCR and published 
sequence specific primers as described (22-29; see Table 1 in Appendix I for the primer 
sequences and expected sizes of the amplicons for the genes). Standard PCR protocols 
were used. The general procedure included initial denaturation at 95˚C for 5 minutes 
followed by 30-35 cycles, each comprising 30 seconds of denaturation at 95˚C, 30 
seconds of annealing at 60-68˚C and 2 minutes of extension at 72˚C. The final cycle 
included extension for 10 minutes. The number of PCR cycles and annealing 
temperatures were adjusted for each gene in preliminary experiments. The presence or 
absence of the genes was determined by running the reaction products on 2-2.5% agarose 
gels. The gels were stained with ethidium bromide, scanned and imaged. The appearance 
of the amplicon band of the expected molecular weight (see Figure 1 in the Appendix II 
for a few typical agarose gel images) was considered as the presence of the gene in the 
genomic DNA sample.  The DNA samples known to be positive or negative for the gene 
were used as positive and negative controls, respectively. The PCR reactions were also 
run without DNA template as a safeguard against false positive cases as well as for a 
housekeeping gene, GAPDH, as a control for false negative cases.  
Despite all the precautions, the PCR reactions for a few samples (5 control and 2 B-ALL 
samples) did not succeed and were excluded from the analyses.   
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Statistical analysis: 
 
Based on the genotyping, patients were classified as those in whom the gene was present 
or absent. As we could not distinguish between heterozygotes and homozygotes for the 
presence of a gene, it was not possible to examine deviation from Hardy-Weinberg 
Equilibrium for the studied genes. Initial analysis included examining the distribution of 
the genes in cases and controls using Chi-square tests. Subsequently, logistic regression 
analysis was carried out. A single model for each gene as the independent variable was 
first fit. As many of the KIR genes are in high linkage disequilibrium with each other, a 
multivariate model including all 5 genes was then fit to assess the independent effect of 
each gene after controlling for the effects of other genes. In addition to the effect of 
individual genes, we also assessed the combined effects of harbouring 1 or more 
activating genes in comparison with not harbouring any of the genes. For this an analysis 
considering the carriage of activating genes as a continuous variable as well stratified into 
categories (≤1, between 2-3 and ≥4) was also carried out. Odds ratios (OR) and 
corresponding 95% confidence intervals (95% CI) were estimated. All analyses were 
carried out using STATA software (version 10; STATA Corp, TX, USA). 
 
RESULTS: 
 
A total of 100 cases and 245 controls were successfully genotyped. Table 1 shows the 
comparison of the distribution of individual activating KIR genes between patients and 
controls as well as results from univariate analysis. The frequencies of all the 6 activating 
KIR genes were lower in the patients compared with the controls. Consequently, all of 
these genes were associated with significantly dcreased risk for developing pre-B ALL. 
Strongest associations were noted with the KIR2DS2 gene wherein the presence of the 
gene decreased the risk for developing pre-B ALL by ~80% (OR=0.19, 95% CI=0.11-
0.34, p-value= 5.4 x 10-9). When a multivariate logistic model was fit, after accounting 
for the effects of other genes, the protective association between the KIR2DS2 gene 
persisted and was of similar magnitude (OR=0.23, 95% CI=0.13-0.42, P=2.7 x10-6), 
indicating that the protective effects conferred by the gene were independent of other 
KIR genes that could be in high LD (linkage disequilibrium) with it. Associations with 
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the KIR2DS1 and KIR2DS3 genes however were no longer evident in the multivariate 
analysis, suggesting that the effects of these genes were not independent but were as a 
result of their being in high LD with other KIR activating genes. The KIR2DS1 gene also 
seemed to confer protection, but this association did not achieve statistical significance. 
As mentioned in the introduction, KIR2DS4 is frequently mutated and shows a 22-bp 
deletion, which results in the expression of a non-functional receptor. In the analysis 
shown in Table 1, we counted the individuals showing only this 22-bp mutant form as 
being negative for the gene. The individuals were considered positive for the gene when 
non-mutated amplicon band was seen on the gel with or without the presence of the 
mutated band. 
We also took into consideration whether the individuals had only mutant form, only wild 
type functional form, had both functional and mutated genes or had neither functional nor 
mutated genes. We compared the cases and controls with respect to the frequencies of 
these four KIR2DS4 genotypes. As shown in Table 2, we observed that children who had 
an active and a mutant gene were protected from risk for pre-B ALL (OR=0.35, 95% CI= 
0.18-0.69, p= 0.003). There were suggestions that those who carried 2 active genes were 
also protected from pre-B ALL however the magnitude of the protection was lower than 
that observed for children who carried 1 mutant and 1 active gene.   
There existed a statistically significant trend towards increased protection with increasing 
numbers of inherited activating KIR genes. The analysis showed that with each additional 
activating gene, the risk decreased by 0.435 (OR: 0.4350601, SE: 0.050248, z: -7.21,  
P>z : 0.000, and 95% CI: 0.3469271-0.5455824). The effects of inheriting multiple 
activating genes on protection from the childhood leukemia are shown in Table 3. The 
results suggest that individuals who harboured increasing number of the genes were less 
susceptible for pre-B ALL. The strongest protection was observed in individuals who 
harboured any 4 or more KIR activating genes (OR=0.07, 95% CI= 0.03-0.18, P=3.60 x 
10-9).  
 
DISCUSSION 
 
In this case-control study we investigated whether activating KIR genes were associated 
with susceptibility/resistance to pre-B ALL in a French-Canadian population. We 
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observed that all six activating KIR genes tended to confer protection from acquiring pre-
B ALL (P<0.05; Table 1). However, in a multivariate analysis four of these genes 
(KIR2DS2, KIR2DS4, KIR2DS5 and KIR3DS1) conferred protection independent of the 
effects of the other genes. There were also suggestions that the protective effects of the 
activating genes were additive.  
To the best of our knowledge, this is the first study that has described the protective 
effects of activating KIR genes on an individual’s susceptibility to develop pre-B ALL in 
a French-Canadian population. A few earlier studies, focussed on adult populations, have 
described the associations of KIR genes with other leukemias in different human 
populations. For example, one group (30, 31; reviewed in 32) has shown potential 
associations of certain inhibitory KIR-HLA gene interactions, but not of activating KIR 
genes, with chronic lymphoid (CLL) and myeloid leukemias (CML) in the Belgian 
population. No associations with ALL were noted; however, given the small number of 
ALL patients evaluated (n=8), the study had limited power to demonstrate meaningful 
associations. Furthermore, the researchers did not discriminate between functional and 
mutant variants of the KIR2DS4 gene. Another study conducted in Polish and German 
individuals discriminated between functional KIR2DS4 and its mutant variants (16). The 
researcher found a protective effect of the gene in CML but not in ALL patients. Similar 
to the previous study, they also had limited power (n= 21) to detect significant 
associations if any with ALL. All the patients in the study were of Polish origin, while 
controls comprised individuals from Polish and German descents. Given the widespread 
heterogeneity in KIR gene frequencies, confounding due to ethnicity cannot be ruled out 
in this study. A more recent study in Chinese populations (18) has shown that activating 
KIR genes were more frequent in CML patients than in healthy controls, although the 
difference for only KIR2DS4 genes reached statistical significance. The study also did 
not discriminate between mutant and functional variants of the gene. The researchers also 
found a significantly (P=0.029) decreased frequency of KIR2DS3 in ALL patients 
compared to the control group.  
It is noteworthy that all the previous studies (16, 18, 30, 31) have attempted to examine 
the association between KIR genes and adult-onset leukemia. These studies did not 
include childhood leukemias. Further, comparison is hampered given that early-onset 
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leukemia may involve different susceptibilities and differing etiologies vis-à-vis adult-
onset leukemia. Furthermore, even within childhood leukemias, etiologies for ALL may 
differ between the different forms (Pre-B ALL and ALL with unspecified cell types). In 
order to reduce this heterogeneity and given that Pre-B ALL is the predominant form of 
all childhood leukemias (85% of the leukemias occurring in children under 15 years of 
age; 1, 6) we focussed on this phenotype. In this context, we excluded cases of childhood 
leukemia of T cell phenotype (T-ALL) or of unspecified cell phenotypes to avoid 
concerns about their potentially different etiologies.  
KIR gene frequencies are known to vary between and within populations. Thus the 
choice of the control population is of paramount importance. Our healthy controls were 
drawn from a variety of sources so that they represented the population frequencies of the 
selected genes. Secondly, both cases and controls were restricted to a common ancestry 
reducing potential ethnic heterogeneity. It is noteworthy that the KIR gene frequencies 
within the control populations are reflective of the distribution within other populations 
of similar ancestry (Belgian and French) (http://www.allelefrequencies.net), further 
demonstrating that bias if any, in the selection of controls was limited. Thus, a relatively 
large number of patients, more relevant control donors (with respect to ethnicity) and a 
precisely defined leukemic condition may have been responsible for the results obtained 
in our study. Our findings of significant protection conferred from pre-B ALL will thus 
require confirmation in an ethnically similar population with a similar disease phenotype.  
It is noteworthy that KIR genes mainly control functional activities of NK cells, which 
are important effector cells of the innate immune system. They can efficiently kill most 
tumor cells in the body without prior sensitization and amplification (9, 33-35). In 
particular, these cells kill target cells of hematopoietic origin more efficiently than target 
cells of non-hematopoietic origin. They have been shown to kill autologous and 
heterologous leukemia cells in in vitro assays (35, 36). The protective role of activating 
KIR genes from childhood leukemia suggests that the individuals with these genes are 
likely to a) recognize and kill the leukemic cells via these receptors on their NK and/NKT 
cells, b) are likely to have lower threshold of activation of their NK and other immune 
cells (e.g., CD8+ T cells) and provide better immune surveillance against malignancy, and 
c) the NK cells with activating receptors can better induce anti-cancer adaptive immunity. 
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These mechanisms may not be mutually exclusive. In fact as mentioned above, NK cells 
have been demonstrated to kill autologous leukemic cells in vitro (32). The role of these 
cells in controlling leukemia is further supported by the reports that infusion of 
mismatched alloreactive NK cells (which bear activating KIR and/or inhibitory KIR 
whose cognate HLA ligands are missing in the recipients) into leukemia patients provides  
NK cells expressing activating KIR genes may prove more beneficial in children 
suffering from Pre-B ALL.  
Unlike their homologous inhibitory receptors, activating NK cell receptors bind to 
specific HLA- class I ligands with very low affinities. In fact it is believed that these 
activating receptors may bind to the ligands that are expressed de novo in cancer or virus-
infected cells and/or they may recognize foreign peptides bound with HLA-class I 
peptides. In the case of KIR2DS4, the receptor was described to bind an unidentified 
ligand expressed by primary melanoma cells (38). 
Interestingly, the KIR3DS1 gene, which has been shown to be protective for Pre-B ALL 
in this study, has been associated with protection from infection with the type 1 Human 
Immunodeficiency Virus (HIV-1) as well as with delayed progression of the infection 
towards AIDS (15, 39). In fact, KIR3DS1 is the collective name given to several allelic 
variants of KIR3DL1. These variants encode a short-tailed activating version of the 
receptor. KIR3DL1 is one of the most polymorphic genes in the KIR family. It exists in 
59 allelic variants of which 13 encode short-tailed activating version of the receptor and 
hence are collectively designated as KIR3DS1, whereas the remaining 46 allelic variants 
encode long-tailed inhibitory version of the receptor and are designated as KIR3DL1 (7, 
8, 9).  Researchers have discovered that KIR3DL1 receptors bind HLA-Bw4 allotypes 
that have an isoleucine (Ile) at position 80 in their α-1 domain. The activating versions of 
the receptor were shown to bind the HLA-Bw4 allotypes with threonine (Thr) at position 
80. However, the subsequent studies have not confirmed these observations (7, 8, 10). 
Therefore, like other short cytoplasmic tail activating KIR, the exact ligands for 
KIR3DS1 remain unknown. In fact, even in the cases, where some activating KIR 
receptors have been shown to bind MHC class I ligands, the binding had been of low 
affinities (40; reviewed in 9). Our results suggest that the presence of activating KIR 
genes may facilitate activation of NK cells, CD8+ T lymphocytes (CTL) and NK-T cells 
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in cancers and viral infections. Hence they may provide protection from viral infections 
and malignancy. Interestingly our results about Pre-B ALL patients fit with this 
paradigm.  
In conclusion, our study demonstrates important protective effects of KIR gene variation 
and B-ALL. Larger studies are required to replicate these findings in different ethnic 
populations.  
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Table 1. The comparison of frequencies of activating KIR genes in Pre-B ALL patients 
and healthy controls 
------------------------------------------------------------------------------------------------------------ 
 
Gene Patients  Controls OR (95% CI) P-values ORadj (95% CI)* Padj-values* 
 
 N (%)  N (%) 
 N=100  N=245 
--------------------------------------------------------------------------------------------------------------------- 
2DS1 28 (28.3) 102 (41.6) 0.55 (0.33-0.92) 0.02  0.65 (0.37-1.17) 0.15 
2DS2 20 (20.0) 138 (56.3) 0.19 (0.11-0.34) 5.4 x 10-9 0.23 (0.13-0.42)    2.7x 10-6 
2DS3 14 (14.1)   83 (33.9) 0.32 (0.17-0.60) 3.7 x 10-4 0.64 (0.31-1.30) 0.22 
2DS4a 38 (39.2) 139 (56.7) 0.49 (0.30-0.79) 0.004  0.48 (0.28-0.82) 0.008 
2DS5 19 (19.2) 104 (42.4) 0.32 (0.18-0.56) 7.5 x 10-5 0.37 (0.20-0.70) 0.002 
3DS1 16 (16.0) 101 (41.2) 0.27 (0.15-0.49) 1.57 x 10-5 0.44 (0.23-0.84) 0.014 
 
----------------------------------------------------------------------------------------------------------------------- 
 
* Logistic regression estimates after adjusting for the effects of other genes.  
The superscript “a” indicates that KIR2DS4 was considered absent when the PCR 
amplified only the 32-bp deleted amplicon. It was considered present when the non-
mutant amplicon was observed on the gel with or without the mutant band.  
Please note that the prefix KIR is not shown with the gene names.  
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Table 2. Comparison of frequencies of mutant and functional KIR2DS4 genes in Pre-B 
ALL patients and healthy controls 
------------------------------------------------------------------------------------------------------------ 
 
Gene Type  Patients  Controls OR (95% CI)  P-value 
Absenta or Mutantb 59 (60.8)  106 (43.3) Reference 
Active/Mutant  13 (13.4)  66 (26.9) 0.35 (0.18-0.69) 0.003 
Active/No Mutant 25 (25.8)  73 (29.8) 0.62 (0.35-1.07) 0.086 
------------------------------------------------------------------------------------------------------------ 
 
a: Absent means that no band (mutant or full length) was detected in the genome. 
b: Mutant means the presence of a 32-bp deleted non functional gene. 
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Table 3. Comparison of frequencies of different numbers of activating KIR genes 
between Pre-B ALL patients and healthy controls 
------------------------------------------------------------------------------------------------------------ 
Number of genes Patients  Controls OR (95% CI)  P-value 
<=1   60 (60.0)  48 (19.6) Reference 
2-3   33 (33.0)  122 (49.8) 0.22 (0.13-0.37) 2.8 x 10-8 
>=4   7 (7.0)    75 (30.6) 0.07 (0.03-0.18) 3.6 x 10-9 
--------------------------------------------------------------------------------------------------------------- 
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CHAPTER 4 
 
DISCUSSION 
 
    In a case control study, we examined whether activating KIR genes were associated 
with susceptibility/resistance to pre-B ALL. We investigated 100 cases of B-ALL, which 
were in French-Canadians residing in the Province of Quebec. Furthermore, all of our 
cases were of B-ALL type. We excluded T-cell ALL and other ALL cases that were not 
of B-cell origin. Since ALL cases originating in children in different cell lineages may 
differ from each other with respect to their etiologies and could be a confounding factor, 
we decided to focus on the ALL cases originating in the B-cell lineage. It is noteworthy 
that B-ALL represents 85% of the leukemia occurring in children under 15 years of age 
(1-3). Our healthy control group consisted of 245 children drawn from the general 
population and belonging to the same ethnic origin as the cases. We observed that all 
activating KIR genes have a tendency to be associated with protection from childhood 
leukemia, as the frequencies of all these genes were significantly lower in patients than in 
the controls (P<0.05). However, in analyses for independent effects of each gene, four of 
these genes (KIR2DS2, KIR2DS4, KIR2DS5 and KIR3DS1) conferred statistically 
significant protection from this type of childhood leukemia. 
    To the best of our knowledge, this is the first study that has described significant 
associations of activating KIR genes with an individual’s innate resistance to developing 
B-ALL in a French-Canadian population. We could not find any report in the literature 
that has investigated the association of KIR genes (activating or inhibitory ones) with 
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childhood leukemia. There are a few studies that have reported the associations of KIR 
genes with AML, CML, CLL or ALL in adults. One of the studies (9) investigated 
potential associations of 11 KIR genes, 2 NKG2/CD94 genes and different KIR-HLA 
interactions with different types of leukemia in Belgian adults. The study included a 
relatively small number of patients: 8 ALL, 29 AML, 20 CML and 39 CLL patients. 
Nevertheless, the study found that certain inhibitory AB KIR haplotypes were more 
frequent in leukemia patients as compared to the control subjects. The authors concluded 
that leukemia develops in individuals whose NK cells are more tightly inhibited by their 
inherited KIR and HLA genes. The same group of researchers performed another study 
on this subject (74). The cases in this study were all adults and comprised 31 CLL and 48 
CML. They found significant associations of certain KIR-HLA combinations with these 
leukemia types. The authors concluded that KIR-HLA-mediated NK cell control is an 
important factor in the development of CLL and CML in adult humans. Another group of 
researchers (80) investigated the potential association between leukemia and KIR2DS4 
polymorphism in Polish and German adult individuals. The gene is often present on the 
group A KIR haplotypes and is often mutated and non-functional (72). The workers 
differentiated between functional KIR2DS4 and its mutant 22 bp-deleted variant in their 
study. The study found significant associations of the functional gene with innate 
resistance to developing CML but not ALL. A drawback of this study is that it had a 
relatively small number of ALL cases (only 21).  Due to this relatively small number of 
ALL patients, the study had too low power to detect any potential association between 
this activating KIR gene and ALL. Furthermore, all of the patients in the study were of 
Polish origin, while the controls comprised individuals from Polish and German descent. 
It is possible that mixed ethnic origins of the control population may have also affected 
the results. 
    Recently, a study on the potential associations between KIR genes and different types 
of leukemia has been reported in a Chinese population (81). The researchers found 
increased frequencies of activating KIR genes in CML patients versus those in healthy 
controls, although the difference reached statistical significance only for the KIR2DS4 
gene. This study, however, did not differentiate between the functional and mutant 
variants of the KIR2DS4 gene. It is noteworthy that about 80% of Caucasians harbor a 22 
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bp deletion in exon 5 of the gene, which renders the gene non functional (7, 72). The 
frequency of the mutant KIR2DS4 in Chinese is not known.  Had the researchers taken 
into consideration this mutation, their results could have been more reliable. The 
researchers also found a significantly (P=0.029) decreased frequency of KIR2DS3 in 
ALL patients compared to the control group. However, the study included only adult 
ALL patients, and not children.  
    Taken together, the studies in adults suggest that KIR genes especially the activating 
ones as well as certain KIR-HLA gene interactions play an important role in determining 
innate resistance/susceptibility of human adults to developing leukemia (reviewed in 82). 
For various reasons, the results from our study cannot be compared with those from 
earlier studies. The main reason is the difference in the patient population: all of the 
previous studies were based upon adult patients whereas our study is based only on 
children less than 15 years of age. Furthermore, all of the previous studies did not focus 
on one type of leukemia. In contrast, our study has focused on one well-defined 
childhood leukemia i.e., B-ALL. We have even eliminated childhood leukemias of T cell 
origin (T-ALL). Furthermore, we have a larger number of leukemia cases as compared 
with the previous studies. Thus, a homogenous group of patients with respect to ethnicity, 
better defined childhood leukemia and a relatively large number of cases and controls 
may have been responsible for detecting significant associations between activating KIR 
genes and B-ALL in our study.  
    The demonstration of significant associations between activating KIR genes and a 
reduced risk for developing B-ALL suggests that NK cells have a role in controlling this 
cancer. It is worth noting that NK cells were discovered as a result of their ability to kill 
certain tumour cell lines (83).  NK cells recognize and eliminate cells that fail to express 
self-MHC molecules. In particular, these cells kill target cells of hematopoietic origin 
more efficiently than target cells of non-hematopoietic origin. They have been shown to 
kill autologous and heterologous leukemia cells in in vitro assays (83, 84). The cytolytic 
activity of human NK cells is regulated by overall strengths of inhibitory and activating 
signals emanating from a diverse array of inhibitory and activating receptors and 
coreceptors. These receptors bind to their cognate ligands present on the surface of cancer 
cells. KIR receptors play a predominant role in deciding whether a NK cell kills or spares 
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a target cell (65, 66). The protective role of activating KIR genes from childhood 
leukemia suggests that the individuals with these genes are likely to: 
a) Recognize and kill leukemic cells via these receptors on their NK and/NKT cells. 
b) Have a lower threshold of activation of their NK and other immune cells (e.g., CD8+ T 
cells) and provide better immune surveillance against malignancy.  
c) The NK cells with activating receptors can better induce anti-cancer adaptive 
immunity.  
    These mechanisms may not be mutually exclusive. In fact, as mentioned above, NK 
cells have been demonstrated to kill autologous leukemic cells in vitro (84, 85; reviewed 
in 82). The role of these cells in controlling leukemia is further supported by reports that 
the infusion of mismatched alloreactive NK cells (which bear activating KIR and or 
inhibitory KIR whose cognate HLA ligands are missing in the recipients) into leukemia 
patients provides significant graft versus leukemia effects (82). In a study investigating 
the influence of donor and recipient KIR genotypes on the outcome of hematopoietic cell 
transplantation between HLA-matched siblings in CML patients (84), the researchers 
found that the best survival rate was associated with the donor lacking and the recipient 
having group B KIR haplotypes (group B haplotypes are comprised of more than one 
activating KIR gene); the poorest survival rate was associated with the donor having and 
the recipient lacking group B KIR haplotypes. The latter combination was also associated 
with increased relapse and acute GVHD. The results from stem cell transplantation in 
leukemic patients strongly suggest a role of NK cells as well as of KIR receptors and 
their ligands in deciding the outcome of the graft and leukemic control.  
    In our results, we have found that KIR3DS1 has a protective effect in ALL. A previous 
study (76) has shown that the presence of an activating KIR3DS1 along with the co-
expression of its ligand, i.e., the HLA-Bw4 allotypes, confers resistance to the 
development of AIDS in HIV-infected patients. It is worth pointing out that KIR3DS1 
represents allelic variants of KIR3DL1, which exist in 59 allelic variants, 13 of which 
encode a short tailed activating receptor while the other 46 allelic versions encode long 
tailed inhibitory versions of the receptor. KIR3DL1 receptors bind HLA-Bw4 allotypes 
that have an isoleucine (Ile) at position 80 in their α-1 domain. On the other hand, the 
exact ligand for KIR3DS1 remains uncertain. Some studies suggest that KIR3DS1 binds 
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the HLA-Bw4 allotypes with threonine (Thr) at position 80. However, several reports 
were unable to verify these results (reviewed in 73). 
    As is the case for KIR3DS1, the ligands for most other activating KIRs remain 
unknown. It is believed that the ligands for these receptors may be induced on some 
tumor cells. In this respect, KIR2DS4 was reported to bind an uncharacterized ligand on 
certain melanoma cells (87). Considering the protective role of activating KIR genes in 
childhood leukemia, it would be important to search for ligands for these receptors.  
It is noteworthy that activating KIR genes have been shown to protect humans from 
several viral infections, e.g., HCV and HIV (76, 78). Our results suggest their protective 
role in childhood leukemia. They are in agreement with the paradigm that activating KIR 
genes and less inhibitory KIR-HLA interactions protect humans from infectious agents 
and malignancy by enhancing NK cell activities and overall immune competence of the 
host. However, this protection comes with a price, as many of the activating KIR genes 
have also been shown to enhance an individual’s susceptibility to autoimmune diseases 
like arthritis and type 1 diabetes (10, 77). 
    Our results may bear important implications for B-ALL. They may provide impetus to 
discovering ligands for activating KIRs. It is tempting to speculate that B-ALL cells may 
express ligands for these receptors. The discovery of these receptors may lead to novel 
KIR-based drugs for treating leukemia in humans. 
    Another implication of our study is that the results may be used to identify children at 
higher risk for developing this cancer. These results predict that children lacking 
activating KIR genes are at high risk for developing leukemia. An early detection and 
treatment of the cancer has better prognosis for the patients (21, 88).  
    The results from our study may have implications in bone marrow grafts in B-ALL 
patients. These results suggest that infusions of bone marrow stem cells from donors 
having activating KIR genes may be more effective in eliminating the cancer. 
Furthermore, infusions of NK cells expressing activating KIR genes may prove to be 
more beneficial in children suffering from this cancer. It is noteworthy that alloreactive 
NK cells, whether infused into recipients or develop in recipients due to mismatches 
between donors and recipients, reduce graft-versus-host disease, kill leukemic cells and 
diminish relapses in bone marrow transplants (66, 89).   
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The protective role of activating KIR genes from childhood leukemia is likely to be 
modulated by the presence of inhibitory KIR genes and their MHC class I ligands. 
Studies are currently underway in our laboratory to investigate the potential impact of the 
inhibitory KIR on the protective effects of the activating KIR genes. 
    Finally, we have demonstrated the association of activating KIR genes with reduced 
risk for B-ALL in French-Canadian children. Further studies are needed to replicate these 
results in ethnically different populations. 
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CHAPTER 5 
 
CONCLUSIONS 
 
   
    Based upon our case control study, in which we used genomic DNA from 100 B-ALL 
children and 245 healthy controls, we conclude that activating KIR genes (KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1) are associated with a 
decreased risk for developing this childhood leukemia. The frequencies of all of these 
genes were significantly reduced in the B-ALL cases as compared to those observed in 
healthy children. Furthermore, the number of these genes shows a significant linear 
association with resistance to developing this cancer. This finding suggests additive 
effects of the activating KIR genes in providing protection from developing this cancer in 
children. Furthermore, we also stratified the individuals in both cases and controls in 
three categories, i) as having 0 or 1, ii) having 2 or 3, and iii) having more than 4 
activating KIR genes. When we compared the frequencies of the individuals between 
cases and controls in the three categories, the difference between the frequencies of the 
genes in the patients and controls increased as the number of the genes examined 
increased, i.e., from category i to iii. We conclude from this data that the risk for 
developing B-ALL increases as the number of inherited activating KIR decreases in 
children.  
    In a univariate logistic regression analysis, all activating KIR genes were associated 
with a decreased risk for developing B-ALL. However, in a multivariate analysis, only 
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four of the genes (KIR2DS2, KIR2DS5, KIR2DS4, and KIR3DS1) showed significant 
association with decreased risk for developing this cancer. In this analysis, KIR2DS1 and 
KIR2DS3 lost significance. However, the frequencies of these two genes were still lower 
in cases compared with the healthy controls. It is highly probable that if a larger study 
would be conducted with a larger number of cases, the results for these two genes could 
also be significant. 
    The association of activating KIR genes with reduced risk for childhood leukemia 
strongly suggests the involvement of NK cells in controlling this cancer. NK cells bearing 
activating KIR are likely to kill B-ALL cells. These predictions can be tested in in vitro 
experiments. Our results also suggest that B-ALL cells are likely to express ligands for 
activating KIRs. Finding these ligands should be an area of high priority research. For 
this purpose, the use of B-ALL cells may be more promising. Their discovery may lead 
to novel KIR-based therapies for B-ALL in the future.   
    Our results also bear implications for bone marrow transplantations that are often 
carried out in leukemic children. They suggest that bone marrow stem cells from the 
donors that are positive for one or more activating KIR genes may prove to be more 
successful in controlling leukemia. Furthermore, our results also suggest that infusions of 
NK cells expressing activating KIR may be used as a therapeutic strategy in controlling 
and treating childhood leukemia. Such NK cells may be enriched from autologous or 
heterologous sources. 
    Further studies should be carried out to replicate these results in other ethnic 
populations. If validated, the results may be helpful in the early identification of children 
who are at-risk for developing this most frequent childhood leukemia. 
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APPENDIX 1 
 
 
Table 1.  Sequence-specific primers used for PCR amplification of activating KIR 
genes.  
 
Gene          Primer sequences     Amplicon size        Reference     
   
KIR2DS1 CTTCTCCATCAGTCGCATGAA 102 1 
 AGAGGGTCACTGGGAGCTGAC  
   
KIR2DS2 CGG GCC CCA CGG TTT 240 1 
 GGT CAC TCG AGT TTG ACC ACT CA  
   
KIR2DS3 CTA TGA CAT GTA CCA TCT ATC CAC 190 1 
 AAG CAG TGG GTC ACT TGA C  
   
KIR2DS4 CTG GCC CTC CCA GGT CA 199 or 221 2 
 TCT GTA GGT TCC TGC AAG GAC AG  
   
KIR2DS5 TGA TGG GGT CTC CAA GGG 125 1 
 TCC AGA GGG TCA CTG GGC  
   
KIR3DS1 AGC CTG CAG GGA ACA GAA G 300 1 
 GCC TGA CTG TGG TGC TCG  
   
 
 
All primer sequences are given in 5’ to 3’ orientations. 
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chang Z, Yue-ran Z. Polymorphisms of Killer Cell Immunoglobulin-like 
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APPENDIX 2 
 
 
Figure 1. Images of representative agarose gels for different KIR genes. 
 
 
 
A.KIR2DS3 
 
 
 
 
The Figure shows molecular weight markers in lane1(GeneRuler from Fermentas Cat. 
No. SM1331). The negative and positive controls are shown in lane 2 and 3, respectively. 
The other lanes contain different samples. The presence of  the expected 190 bp band 
indicates presence of the gene.  
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B. KIR2DS1 
 
   
 
The arrow indicates position of the expected band for KIR2DS1(102 bp). The first 
three lanes (from right to left) represent Molecular Weight Marker ladder 
(Fermentas Cat. No. SM1331), a negative and a positive control, respectively. The 
other lanes indicate different samples. The expected band for the gene (upper one) 
is clearly visible in positive samples. 
 
 
 
C. KIR2DS2 
 
 
 
 
The arrow indicates position of the expected band for KIR2DS2 (240 bp). The 
first four lanes represent Molecular Weight Marker ladder (Fermentas Cat. No. 
SM1331), two negative and a positive control, respectively. The other lanes 
indicate different samples. The upper band of the expected size (240 bp)  is 
clearly visible in positive samples. 
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D. KIR2DS4 
 
 
 
 
The amplicons for the KIR2DS4, 221 bp for the intact gene and 199 bp for the mutant 
gene, are shown by right and left arrows, respectively. The first three lanes represent 
Molecular Weight Marker ladder (Fermentas Cat. No. SM1331), a negative and a 
positive control, respectively. 
 
 
 
E. KIR2DS5 
 
 
 
The arrow indicates position of the expected band for KIR2DS5 (125 bp). The first 
three lanes represent Molecular Weight Marker ladder (Fermentas Cat. No. SM1331), 
a negative and a positive control, respectively. The other lanes indicate different 
samples. The upper band of the expected size is clearly visible in positive samples. 
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F. KIR3DS1 
 
 
 
 
The arrow indicates position of the expected band for KIR3DS1 (300 bp). The 
first three lanes represent Molecular Weight Marker ladder (Fermentas Cat. No. 
SM1331), a negative and a positive control, respectively. The other lanes indicate 
different samples. The upper band of the expected size ( 300 bp) is clearly visible 
in positive samples. 
 
 
